

# Welcome

## Understanding Research & Critical Appraisal

---

### Part 2: Studies of Treatment Effectiveness

*For everyone's sake, please be quiet!  
Keep your phone on mute  
until you are ready to ask questions.*

How?

- Press the "mute" button on your phone
- If your phone does not have a mute button, then press \*6 to mute your phone, and \*6 to un-mute.



SENIORS HEALTH RESEARCH TRANSFER NETWORK

Linking Caregivers, Researchers & Policy Makers

# Studies of Treatment Effectiveness

**David L. Streiner, Ph.D.**

**Director, Kunin-Lunenfeld Applied Research Unit**

**Assistant Vice President, Research**

**Baycrest Centre for Geriatric Care**

**Professor, Department of Psychiatry, U of Toronto**

# What We'll Cover

- Issues in designing a randomized controlled trial (RCT)
- Sources of bias
- The outcome

# Setting the Scene

An investigator wants to do a study to look at the effectiveness of cognitive behaviour therapy (CBT) for the treatment of depressed patients.

# Decisions to be Made

Investigators have to decide (explicitly or implicitly):

- What the question is
- Who is studied
- What research design to use
- What the outcome is
- How to analyze the data

*Step 1: What Is The Question?*

# What's the Question?

- Is CBT better than:
  - A wait-list control?
  - Medication alone?
  - Psychotherapy?
  - Psychotherapy + medication?
  - Treatment as usual?

# What's the Question?

- Is CBT equivalent to another therapy but:
  - Less expensive?
  - Longer lasting?
  - Faster acting?
  - More acceptable to the patients?

# The Question


- No study can answer all questions
- Asking one question may preclude asking others.

# Step 2: The Design

# Design

It is generally agreed that, to study treatment effectiveness, the ideal study design is an RCT.

# Design:



# RCT Decisions


- Seems straightforward, but not all RCTs are alike.
- Major decision is between an *efficacy* study and an *effectiveness* study.

# Efficacy and Effectiveness

- Efficacy – *can* the treatment work under ideal circumstances.
- Effectiveness – *does* the intervention work in the real world?

# Efficacy and Effectiveness

Two ends of a continuum



Most studies are somewhere in between

# Efficacy and Effectiveness

Keep this in mind; we'll keep coming  
back to it.


# Step 3: Subjects

# Who Gets Into Trials

- Possible biases
  - Referral filters

# Referral Filters

- Where are studies done?
  - Tertiary care centres
- Who is seen at tertiary care centres?



# Referral Filters

- Where are studies done?
  - Tertiary care centres
- Who is seen at tertiary care centres?
  - The most severe
  - The most unusual
  - The most intractable

# Who Gets Into Trials

- Possible biases
  - Referral filters
  - Diagnostic access

# Diagnostic Access

- Who gets most advanced work-ups?
  - Those in urban centres
  - Those with better insurance (in U.S.)
  - Those with more money (in U.S.)
  - Those with ‘connections’

# Who Gets Into Trials

- Possible biases
  - Referral filters
  - Diagnostic access
  - Admission bias

# Admission Bias

- A.k.a. Berkson's bias
- More likely to find disorder in people hospitalized for other reasons
- Increases prevalence of comorbidities

# Who Gets Into Trials

- Possible biases
  - Referral filters
  - Diagnostic access
  - Admission bias
  - Volunteer bias

# Volunteer Bias

- Volunteers more likely to be:
  - Non-smokers
  - Concerned about health matters
  - More highly educated
  - Employed in professional and skilled jobs
  - Married
  - Protestant or Jewish
  - Active in community affairs

# Who Gets Into Trials

- Possible biases
  - Referral filters
  - Diagnostic access
  - Admission bias
  - Volunteer bias
  - Patient preferences

# Patient Preferences

- Patients have preferences for treatment:
  - Less invasive vs. more invasive
    - Usually prefer less invasive (e.g., drug vs. surgery, therapy vs. drug)
    - But, more invasive if condition is severe
  - Previous experience
- May not volunteer if concerned they may not get treatment of choice

# Who Is Studied?

- What criteria for depression?
- Any age limits?
- Are co-morbid disorders excluded (e.g., substance abuse)?
- Can they be actively suicidal?
- Can patients have had previous treatment?
- What about medications in past 8 weeks?

# Inclusion/Exclusion Criteria

- Let us know exactly who was studied
- Make the study more efficient
- Make the results easier to interpret
- *But:*
- Limit generalizability of results
- Make patients less like yours

# Inclusion and Exclusion Criteria

- Efficacy
  - Diagnoses as pure as possible
  - Patients meet all criteria
  - No comorbidities
  - No concurrent therapy
  - Exclude placebo responders
  - Exclude non-compliers
  - Homogeneous group
  - Small within-group variance
- Effectiveness
  - Anyone for whom therapy may work
  - May not meet all criteria
  - Comorbidities allowed
  - May be cointervention
  - Heterogeneous group
  - Larger within-group variance

# Step 4: The Treatment

# Treatment

- Efficacy
  - Highly experienced therapists
  - Special training
  - Manualized treatment
  - Therapists checked for adherence
  - Patients' blood levels checked often
  - Telephone reminders of appointments
  - Low-volume centres dropped from study
- Effectiveness
  - Typical therapists
  - No extra training
  - More flexibility in what they do
  - Can mix therapies
  - Little monitoring

# Issues With Patients

## 1. Retention

- Patients must remain in treatment for an extended time
- Drop-outs jeopardize validity of the study

## 2. How to maintain contact

- Calls
- Birthday / holiday cards
- Newsletters

## 3. Problems:

- May be an intervention in its own right

# Step 5: Outcomes

# What Is the Outcome?

- Number of hospitalizations?
- Time in hospital?
- Suicidal attempts?
- Diagnosis?
- Scores on a scale of depression?

# Outcomes

- Many of these outcomes may present problems:
  - Number of hospitalizations, number of suicide attempts, days in hospital – data highly skewed.
  - Change in diagnosis – it's binary; need much larger sample size
  - Change on a scale – it's a surrogate measure; it's not what we're interested in

# Conclusions

- RCTs are the gold standard for looking at effectiveness or efficacy of treatments
- They are definitely not fool-proof (or idiot proof)
- At times, resemble pyrites rather than gold
- They are not a substitute for critical analysis

# Thank you

---

Please complete an evaluation of today's session. Open the following URL in your browser.

[https://www.surveymonkey.com/s.aspx?sm=lyevj4XLeaXnjdD6cCvdaA\\_3d\\_3d](https://www.surveymonkey.com/s.aspx?sm=lyevj4XLeaXnjdD6cCvdaA_3d_3d)

And don't forget, next session:

Part 3: Understanding Bias,

Nov. 27/07 10-11 am



**SENIORS HEALTH RESEARCH TRANSFER NETWORK**

Linking Caregivers, Researchers & Policy Makers